{"id":"prochymal","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion-related reactions"}]},"_chembl":{"chemblId":"CHEMBL2108046","moleculeType":"Cell"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It is believed to exert its effects through the release of anti-inflammatory cytokines and growth factors, which help to reduce inflammation and promote healing in damaged tissues.","oneSentence":"Prochymal is a mesenchymal stem cell therapy that aims to modulate the immune system and promote tissue repair.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:12.288Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Graft-versus-host disease"}]},"trialDetails":[{"nctId":"NCT00543374","phase":"PHASE3","title":"Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2007-09-17","conditions":"Crohn's Disease","enrollment":98},{"nctId":"NCT00877903","phase":"PHASE2","title":"Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2009-03-30","conditions":"Myocardial Infarction","enrollment":220},{"nctId":"NCT00482092","phase":"PHASE3","title":"Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2007-09-17","conditions":"Crohn's Disease","enrollment":330},{"nctId":"NCT01233960","phase":"PHASE3","title":"Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2010-11-29","conditions":"Crohn's Disease","enrollment":73},{"nctId":"NCT00690066","phase":"PHASE2","title":"PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2008-06-11","conditions":"Type 1 Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Insulin-Dependent","enrollment":63},{"nctId":"NCT04456439","phase":"","title":"Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)","status":"NO_LONGER_AVAILABLE","sponsor":"Mesoblast International Sàrl","startDate":"","conditions":"Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)","enrollment":""},{"nctId":"NCT00366145","phase":"PHASE3","title":"Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2006-08-17","conditions":"Graft Versus Host Disease","enrollment":260},{"nctId":"NCT00136903","phase":"PHASE2","title":"Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2005-04-27","conditions":"Graft Vs Host Disease","enrollment":32},{"nctId":"NCT00562497","phase":"PHASE3","title":"Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2008-01-31","conditions":"Graft Versus Host Disease","enrollment":192},{"nctId":"NCT01510431","phase":"","title":"Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Mesoblast, Inc.","startDate":"","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT00759018","phase":"","title":"Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD","status":"NO_LONGER_AVAILABLE","sponsor":"Mesoblast, Inc.","startDate":"","conditions":"Graft vs Host Disease, Graft-Versus-Host Disease","enrollment":""},{"nctId":"NCT00826046","phase":"","title":"Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)","status":"NO_LONGER_AVAILABLE","sponsor":"Mesoblast, Inc.","startDate":"","conditions":"Graft-Versus-Host Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mesenchymal Stem Cells","Remestemcel-L","ex vivo cultured adult human mesenchymal stem cells","Prochymal","Ex-vivo Cultured Adult Human Mesenchymal Stem Cells"],"phase":"phase_3","status":"active","brandName":"Prochymal®","genericName":"Prochymal®","companyName":"Mesoblast, Inc.","companyId":"mesoblast-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Prochymal is a mesenchymal stem cell therapy that aims to modulate the immune system and promote tissue repair. Used for Graft-versus-host disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}